BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Funes SC, Ríos M, Gómez-Santander F, Fernández-Fierro A, Altamirano-Lagos MJ, Rivera-Perez D, Pulgar-Sepúlveda R, Jara EL, Rebolledo-Zelada D, Villarroel A, Roa JC, Mackern-Oberti JP, Kalergis AM. Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice. Immunology 2019;158:322-39. [PMID: 31509246 DOI: 10.1111/imm.13119] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Bayo Jimenez MT, Frenis K, Hahad O, Steven S, Cohen G, Cuadrado A, Münzel T, Daiber A. Protective actions of nuclear factor erythroid 2-related factor 2 (NRF2) and downstream pathways against environmental stressors. Free Radical Biology and Medicine 2022. [DOI: 10.1016/j.freeradbiomed.2022.05.016] [Reference Citation Analysis]
2 Cerovic V, Milling S. A specialist antigen storage compartment in dendritic cells to sustain cross-presentation. Immunology 2021;164:399-400. [PMID: 34651319 DOI: 10.1111/imm.13422] [Reference Citation Analysis]
3 Li Y, Ma K, Han Z, Chi M, Sai X, Zhu P, Ding Z, Song L, Liu C. Immunomodulatory Effects of Heme Oxygenase-1 in Kidney Disease. Front Med (Lausanne) 2021;8:708453. [PMID: 34504854 DOI: 10.3389/fmed.2021.708453] [Reference Citation Analysis]
4 Funes SC, Rios M, Fernández-Fierro A, Covián C, Bueno SM, Riedel CA, Mackern-Oberti JP, Kalergis AM. Naturally Derived Heme-Oxygenase 1 Inducers and Their Therapeutic Application to Immune-Mediated Diseases. Front Immunol 2020;11:1467. [PMID: 32849503 DOI: 10.3389/fimmu.2020.01467] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
5 Fernández-Fierro A, Funes SC, Rios M, Covián C, González J, Kalergis AM. Immune Modulation by Inhibitors of the HO System. Int J Mol Sci 2020;22:E294. [PMID: 33396647 DOI: 10.3390/ijms22010294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Robinson S, Thomas R. Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus. Front Immunol 2021;12:654701. [PMID: 34335564 DOI: 10.3389/fimmu.2021.654701] [Reference Citation Analysis]
7 Pourgholaminejad A, Pahlavanneshan S, Basiri M. COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges. Scand J Immunol 2021;:e13131. [PMID: 34936112 DOI: 10.1111/sji.13131] [Reference Citation Analysis]
8 Funes SC, Rios M, Fernández-fierro A, Di Genaro MS, Kalergis AM. Trained Immunity Contribution to Autoimmune and Inflammatory Disorders. Front Immunol 2022;13:868343. [DOI: 10.3389/fimmu.2022.868343] [Reference Citation Analysis]
9 Funes SC, Fernández-Fierro A, Rebolledo-Zelada D, Mackern-Oberti JP, Kalergis AM. Contribution of Dysregulated DNA Methylation to Autoimmunity. Int J Mol Sci 2021;22:11892. [PMID: 34769338 DOI: 10.3390/ijms222111892] [Reference Citation Analysis]
10 Bolouri N, Akhtari M, Farhadi E, Mansouri R, Faezi ST, Jamshidi A, Mahmoudi M. Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus. Inflamm Res 2022. [PMID: 35298669 DOI: 10.1007/s00011-022-01554-6] [Reference Citation Analysis]
11 Liu Y, Wang X, Yang F, Zheng Y, Ye T, Yang L. Immunomodulatory Role and Therapeutic Potential of Non-Coding RNAs Mediated by Dendritic Cells in Autoimmune and Immune Tolerance-Related Diseases. Front Immunol 2021;12:678918. [PMID: 34394079 DOI: 10.3389/fimmu.2021.678918] [Reference Citation Analysis]